Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 3
1961 3
1962 2
1964 1
1968 4
1969 7
1970 2
1971 1
1972 1
1973 2
1976 2
1978 1
1979 3
1980 2
1981 4
1982 1
1983 1
1986 5
1987 4
1988 6
1989 9
1990 12
1991 6
1992 18
1993 17
1994 39
1995 37
1996 26
1997 30
1998 25
1999 24
2000 37
2001 59
2002 40
2003 51
2004 66
2005 67
2006 90
2007 94
2008 117
2009 141
2010 148
2011 120
2012 146
2013 176
2014 175
2015 174
2016 178
2017 199
2018 210
2019 249
2020 254
2021 287
2022 206
2023 192
2024 159
2025 108

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,648 results

Results by year

Filters applied: . Clear all
Page 1
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.
Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, Lefaucheur C, Montgomery RA, Nickerson P, Tullius SG, Ahn C, Askar M, Crespo M, Chadban SJ, Feng S, Jordan SC, Man K, Mengel M, Morris RE, O'Doherty I, Ozdemir BH, Seron D, Tambur AR, Tanabe K, Taupin JL, O'Connell PJ. Schinstock CA, et al. Among authors: ahn c. Transplantation. 2020 May;104(5):911-922. doi: 10.1097/TP.0000000000003095. Transplantation. 2020. PMID: 31895348 Free PMC article. Review.
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Cornec-Le Gall E, Drenth JPH, Gansevoort RT, Harris PC, Harris T, Horie S, Liebau MC, Liew M, Mallett AJ, Mei C, Mekahli D, Odland D, Ong ACM, Onuchic LF, Pei YP, Perrone RD, Rangan GK, Rayner B, Torra R, Balk EM, Gordon CE, Earley A, Mustafa RA, Devuyst O. Torres VE, et al. Among authors: ahn c. Kidney Int. 2025 Feb;107(2):234-254. doi: 10.1016/j.kint.2024.07.010. Kidney Int. 2025. PMID: 39848746 Free article.
Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial.
Lee B, Hong SJ, Rha SW, Heo JH, Hur SH, Choi HH, Kim KJ, Kim JH, Kim HK, Kim U, Choi YJ, Lee YJ, Lee SJ, Ahn CM, Ko YG, Kim BK, Choi D, Hong MK, Jang Y, Kim JS. Lee B, et al. Among authors: ahn cm. Atherosclerosis. 2023 Dec;386:117373. doi: 10.1016/j.atherosclerosis.2023.117373. Epub 2023 Nov 10. Atherosclerosis. 2023. PMID: 37995599 Clinical Trial.
3,648 results